133 related articles for article (PubMed ID: 38151827)
1. Sarcoma in patients with Lynch syndrome and response to immunotherapy.
Shehata MS; Lofftus SY; Park JY; Singh AS; Federman NC; Eilber FC; Crompton JG; McCaw TR
J Surg Oncol; 2024 Mar; 129(4):820-826. PubMed ID: 38151827
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Molecular Assessment of Patients with Lynch Syndrome and Sarcomas Underpinning the Association with
de Angelis de Carvalho N; Niitsuma BN; Kozak VN; Costa FD; de Macedo MP; Kupper BEC; Silva MLG; Formiga MN; Volc SM; Aguiar Junior S; Palmero EI; Casali-da-Rocha JC; Carraro DM; Torrezan GT
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32659967
[TBL] [Abstract][Full Text] [Related]
3. Special features of sarcomas developed in patients with Lynch syndrome: A systematic review.
Poumeaud F; Valentin T; Vande Perre P; Jaffrelot M; Bonnet D; Chibon F; Chevreau C; Selves J; Guimbaud R; Fares N
Crit Rev Oncol Hematol; 2023 Aug; 188():104055. PubMed ID: 37301271
[TBL] [Abstract][Full Text] [Related]
4. Case report: Undifferentiated sarcoma with multiple tumors involved in Lynch syndrome: Unexpected favorable outcome to sintilimab combined with chemotherapy.
Liu J; Chang X; Xiao G; Zhong J; Huang B; Zhang J; Gao B; Peng G; Nie X
Front Oncol; 2022; 12():1014859. PubMed ID: 36457512
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of mismatch repair deficiency in sarcomas.
Doyle LA; Nowak JA; Nathenson MJ; Thornton K; Wagner AJ; Johnson JM; Albrayak A; George S; Sholl LM
Mod Pathol; 2019 Jul; 32(7):977-987. PubMed ID: 30765880
[TBL] [Abstract][Full Text] [Related]
6. Response to anti-PD1 immunotherapy in patients with metastatic cutaneous sarcoma: case reports and literature review.
Vieira AC; Megid TBC; Melo R; Muniz D; Salgues ACR; Barbosa FG; Munhoz RR; Feher O
Oxf Med Case Reports; 2020 Jan; 2020(1):omz138. PubMed ID: 32038880
[TBL] [Abstract][Full Text] [Related]
7. Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
Sena LA; Fountain J; Isaacsson Velho P; Lim SJ; Wang H; Nizialek E; Rathi N; Nussenzveig R; Maughan BL; Velez MG; Ashkar R; Larson AC; Pritchard CC; Adra N; Bryce AH; Agarwal N; Pardoll DM; Eshleman JR; Lotan TL; Antonarakis ES
Oncologist; 2021 Feb; 26(2):e270-e278. PubMed ID: 33215787
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
[TBL] [Abstract][Full Text] [Related]
9. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
Front Immunol; 2021; 12():775761. PubMed ID: 34925348
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary Artery Intimal Sarcoma in a Patient with Lynch Syndrome: Response to an Immune Checkpoint Inhibitor.
Mounai Y; Yoshida T; Ito S; Fukuda K; Shimazu K; Taguchi D; Shinozaki H; Takagi D; Imai K; Yamamoto H; Minamiya Y; Nanjyo H; Shibata H
Case Rep Oncol; 2023; 16(1):21-29. PubMed ID: 36743879
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive genomic analysis of primary bone sarcomas reveals different genetic patterns compared with soft tissue sarcomas.
Zhang Q; Yang Y; You X; Ju Y; Zhang Q; Sun T; Liu W
Front Oncol; 2023; 13():1173275. PubMed ID: 37546405
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Biliary Tract Cancers Associated with Lynch Syndrome.
Cloyd JM; Chun YS; Ikoma N; Vauthey JN; Aloia TA; Cuddy A; Rodriguez-Bigas MA; Nancy You Y
J Gastrointest Cancer; 2018 Mar; 49(1):93-96. PubMed ID: 29238914
[TBL] [Abstract][Full Text] [Related]
13. The contribution of Lynch syndrome to early onset malignancy in Ireland.
Talbot A; O'Donovan E; Berkley E; Nolan C; Clarke R; Gallagher D
BMC Cancer; 2021 May; 21(1):617. PubMed ID: 34039291
[TBL] [Abstract][Full Text] [Related]
14. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas.
Mills A; Zadeh S; Sloan E; Chinn Z; Modesitt SC; Ring KL
Mod Pathol; 2018 Aug; 31(8):1282-1290. PubMed ID: 29559741
[TBL] [Abstract][Full Text] [Related]
16. Case report: A colorectal cancer patient with microsatellite instability-high and
Zhang Q; Hu J; Zhang Y; Li L; Wang T; Qian X
Front Immunol; 2022; 13():953421. PubMed ID: 35990637
[TBL] [Abstract][Full Text] [Related]
17. Current clinical topics of Lynch syndrome.
Tanakaya K
Int J Clin Oncol; 2019 Sep; 24(9):1013-1019. PubMed ID: 29744602
[TBL] [Abstract][Full Text] [Related]
18. Mismatch repair deficiency is rare in bone and soft tissue tumors.
Lam SW; Kostine M; de Miranda NFCC; Schöffski P; Lee CJ; Morreau H; Bovée JVMG
Histopathology; 2021 Oct; 79(4):509-520. PubMed ID: 33825202
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.
Latham A; Srinivasan P; Kemel Y; Shia J; Bandlamudi C; Mandelker D; Middha S; Hechtman J; Zehir A; Dubard-Gault M; Tran C; Stewart C; Sheehan M; Penson A; DeLair D; Yaeger R; Vijai J; Mukherjee S; Galle J; Dickson MA; Janjigian Y; O'Reilly EM; Segal N; Saltz LB; Reidy-Lagunes D; Varghese AM; Bajorin D; Carlo MI; Cadoo K; Walsh MF; Weiser M; Aguilar JG; Klimstra DS; Diaz LA; Baselga J; Zhang L; Ladanyi M; Hyman DM; Solit DB; Robson ME; Taylor BS; Offit K; Berger MF; Stadler ZK
J Clin Oncol; 2019 Feb; 37(4):286-295. PubMed ID: 30376427
[TBL] [Abstract][Full Text] [Related]
20. Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance.
Bielska AA; Chatila WK; Walch H; Schultz N; Stadler ZK; Shia J; Reidy-Lagunes D; Yaeger R
J Natl Compr Canc Netw; 2021 Feb; 19(2):130-133. PubMed ID: 33545685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
